<DrugInformationSummary id="CDR0000811110"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about mirvetuximab soravtansine-gynx
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/mirvetuximab-soravtansine-gynx">Mirvetuximab Soravtansine-gynx</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000734941">mirvetuximab soravtansine</TerminologyLink><GlossaryLink ref="CDR0000810986">mirvetuximab soravtansine</GlossaryLink><USBrandNames><USBrandName>Elahere</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>MEER-veh-TUK-sih-mab SOH-rav-TAN-seen</TermPronunciation><MediaLink ref="CDR0000812267" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000812268" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c424b5-6ccd-48ab-9e88-1986451120e2&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Mirvetuximab Soravtansine-gynx</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c424b5-6ccd-48ab-9e88-1986451120e2&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Mirvetuximab soravtansine-gynx
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000046768" dictionary="Cancer.gov" audience="Patient">Ovarian epithelial</GlossaryTermRef>, <GlossaryTermRef href="CDR0000755773" dictionary="Cancer.gov" audience="Patient">fallopian tube</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000386215" dictionary="Cancer.gov" audience="Patient">primary peritoneal cancer</GlossaryTermRef></Strong> that is folate receptorâ€“alpha positive. It is used in adults whose cancer did not respond to or is no longer responding to <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef> chemotherapy and who have received one to three types of <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapy</GlossaryTermRef>.</ListItem>
   
   </ItemizedList>
  <Para id="_5">Mirvetuximab soravtansine-gynx
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Mirvetuximab Soravtansine-gynx</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/734941">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-elahere-platinum-resistant-ovarian-cancer">Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C102566">Find Clinical Trials for Mirvetuximab Soravtansine</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2022-12-21</DateFirstPublished><DateLastModified>2024-04-24</DateLastModified></DrugInformationSummary>
